nach oben

Diabetologia

Erschienen in:

01.02.2011 | Commentary

Rosiglitazone: a European regulatory perspective

verfasst von: E. Blind, K. Dunder, P. A. de Graeff, E. Abadie

Erschienen in: Diabetologia | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Excerpt

Rosiglitazone, a drug for the treatment of type 2 diabetes, which has been authorised for use in the EU since 11 July 2000, has attracted continuous scrutiny with regard to its cardiovascular safety profile. The European Medicines Agency (EMA)’s scientific committee, the Committee for Medicinal Products for Human Use (CHMP), in its most recent comprehensive review of rosiglitazone (started 8 July 2010 and completed 22 September 2010), concluded that the benefits of rosiglitazone no longer outweigh the risks, and that the marketing authorisation of the drug in the EU should be suspended [1]. …

European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Press release, 23 September 2010. Available from www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf

Cohen D (2010) Rosiglitazone: what went wrong? BMJ 341:c4848CrossRefPubMed

EMEA (2000) European Public Assessment Report (EPAR) initial marketing authorisation documents–Avandia–Scientific Discussion. Available from www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000268/WC500029103.pdf [containing amendments up to 2004]

Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471CrossRefPubMed

Drazen JM, Morrissey S, Curfman GD (2007) Rosiglitazone—continued uncertainty about safety. N Engl J Med 357:63–64CrossRefPubMed

Montori VM, Gandhi GY, Guyatt GH (2007) Patient-important outcomes in diabetes—time for consensus. Lancet 370:1104–1106CrossRefPubMed

Nathan DM (2007) Rosiglitazone and cardiotoxicity—weighing the evidence. N Engl J Med 357:64–66CrossRefPubMed

Psaty BM, Furberg CD (2007) The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 357:67–69CrossRefPubMed

Psaty BM, Furberg CD (2007) Rosiglitazone and cardiovascular risk. N Engl J Med 356:2522–2524CrossRefPubMed

10.

Rosen CJ (2007) The rosiglitazone story—lessons from an FDA Advisory Committee meeting. N Engl J Med 357:844–846CrossRefPubMed

11.

Home PD, Jones NP, Pocock SJ et al (2007) Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 24:626–634CrossRefPubMed

12.

Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125–2135CrossRefPubMed

13.

Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289CrossRefPubMed

14.

Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30CrossRefPubMed

15.

Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411–418CrossRefPubMed

16.

Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191–1201CrossRef

17.

McEvoy B. 2010. Pioglitazone and rosiglitazone cardiovascular safety meta-analyses. FDA Advisory Committee, 13–14 July 2010. Available from www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM224739.pdf

18.

Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL (2010) Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes 3:538–545CrossRefPubMed

19.

EMA (2010) THIN database study on rosiglitazone use. Available from www.encepp.eu/encepp/viewResource.htm?id=1592, accessed 7 October 2010

20.

EMA (2008) Concept paper on the need for revision of the note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus. Available from www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003182.pdf

21.

Lehman R, Yudkin JS, Krumholz H (2010) Licensing drugs for diabetes. BMJ 341:c4805CrossRefPubMed

22.

EMA (2010) Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus—draft. Available from www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/02/WC500073570.pdf

23.

US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (2008) Guidance for Industry. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention—draft. Available from www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf

24.

UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef

25.

US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (2008) Guidance for Industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available from www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf

Titel: Rosiglitazone: a European regulatory perspective
verfasst von: E. Blind
K. Dunder
P. A. de Graeff
E. Abadie
Publikationsdatum: 01.02.2011
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 2/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-010-1992-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Rosiglitazone: a European regulatory perspective

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Screening for gestational diabetes mellitus: cost–utility of different screening strategies based on a woman’s individual risk of disease

The stress of starvation: glucocorticoid restraint of beta cell development

Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort

Translationally controlled tumour protein (TCTP) is a novel glucose-regulated protein that is important for survival of pancreatic beta cells

Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study

Adenylyl cyclase 8 is central to glucagon-like peptide 1 signalling and effects of chronically elevated glucose in rat and human pancreatic beta cells

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Update Innere Medizin